Parkman Healthcare Partners LLC Buys 73,205 Shares of LivaNova PLC (NASDAQ:LIVN)

Parkman Healthcare Partners LLC increased its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 72.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,934 shares of the company's stock after buying an additional 73,205 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.32% of LivaNova worth $8,101,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. KBC Group NV increased its holdings in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after purchasing an additional 56,580 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after acquiring an additional 1,424 shares during the period. Rhumbline Advisers increased its stake in shares of LivaNova by 0.5% in the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after acquiring an additional 899 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of LivaNova in the 4th quarter worth $2,772,000. Finally, Envestnet Asset Management Inc. increased its stake in shares of LivaNova by 15.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after purchasing an additional 5,850 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $44.06 on Wednesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock's 50 day moving average is $38.06 and its 200-day moving average is $45.03. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $63.57. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 104.90 and a beta of 0.84.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on LIVN shares. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. The Goldman Sachs Group reduced their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Mizuho lowered their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus decreased their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Finally, Robert W. Baird upped their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $59.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.